Phathom Pharmaceuticals
PHAT
103 hedge funds and large institutions have $613M invested in Phathom Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 41 increasing their positions, 20 reducing their positions, and 9 closing their positions.
869% more call options, than puts
Call options by funds: $6.18M | Put options by funds: $638K
211% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 9
179% more capital invested
Capital invested by funds: $220M → $613M (+$393M)
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
105% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 20
23% more funds holding
Funds holding: 84 → 103 (+19)
4.79% more ownership
Funds ownership: 73.35% → 78.15% (+4.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$19.6M |
| 2 |
MVM
Medicxi Ventures Management
St. Helier,
Jersey
|
+$14.7M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$14.7M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$13.3M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$12.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.54M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$2.28M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.98M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$1.14M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$957K |
PHAT Hedge Fund Activity: Q2 2023 in Review
103 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q2 2023, worth a combined $613M — up 179% from $220M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new PHAT positions and 9 closed out — a net gain of 19 holders — while 41 added to existing stakes and 20 trimmed.
The largest buyer was Frazier Life Sciences Management, adding an estimated $19.6M. The largest seller was Opaleye Management, exiting entirely with an estimated $3.54M sold.
- 103 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q2 2023, up from 84 in Q1 2023.
- Funds reported $613M of Phathom Pharmaceuticals stock for Q2 2023, up 179% quarter-over-quarter.
- 28 funds opened new Phathom Pharmaceuticals positions in Q2 2023 and 9 closed out, a net change of +19 holders.
- The largest Phathom Pharmaceuticals buyer in Q2 2023 was Frazier Life Sciences Management, an estimated $19.6M added.
- The largest Phathom Pharmaceuticals seller in Q2 2023 was Opaleye Management, an estimated $3.54M sold.
Based on aggregated 13F filings for Q2 2023.